MANE Veradermics, Inc Insider Trading

Director Suvretta Capital Management buys 282,674 shares for $10.5M across 19 transactions (Feb 4-6)

Suvretta Capital Management, as a Director at Veradermics, executed 19 separate purchases totaling 282,674 shares for $10,542,477.61 at a blended average price of $37.30 across three trading days, increasing holdings by 118.9% from 237,779 to 520,453 shares. The stock was recently listed (4 trading days at the time of filing), making this a substantial foundational position acquisition during the early trading phase. A cluster pattern is evident, with 4 other insiders also purchasing within the past 14 days, indicating coordinated early accumulation among the director group. The multi-day, multi-tranche execution and scale of this purchase ($10.5M) represent material commitment to the position in the stock's nascent public trading phase.

Director John W. Childs bought 294,117 shares of MANE at $17.00 ($5.0M) amid cluster buying by 4 other insiders in 14 days.

Director John W. Childs purchased 294,117 shares at $17.00 on 2026-02-05, expanding his holdings from 1,907,889 shares to 2,202,006 shares (a +15.4% increase). This transaction is part of a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence in the company following its very recent listing (2 trading days prior to this filing). The buy price of $17.00 compares to the current market price of $37.16, establishing a baseline for monitoring whether near-term momentum persists or reverses. Note: This filing involves a conversion of derivative securities; the insider's full position may exceed the Table I holdings shown, pending Form 4 Table II population.

Director Enright buys 1,075,000 shares at $17.00 for $18.3M; cluster pattern with 4 other insiders buying in past 14 days.

Director Patrick G. Enright executed 2 separate purchases totaling 1,075,000 shares at $17.00 on 2026-02-05 for $18,275,000.00, increasing his holdings from 978,474 shares to 2,053,474 shares—a +109.9% increase. This filing occurs at a time of significant cluster activity, with 4 other insiders also buying within the past 14 days, suggesting coordinated interest at the post-IPO entry point. The transaction occurred 2 trading days after listing, at a price $20.16 below the current market price of $37.16. However, the presence of a derivative-conversion element noted in this filing means Enright's full position extends beyond the Table I shares shown, and the reported holdings do not represent his complete stake; investors should review Form 4 Table II when available for the full derivative picture before drawing conclusions about net exposure changes.

Longitude Capital Partners V acquired 1,075,000 shares (1.08M) at $17.00 totaling $18,275,000 in 2 transactions; holdings surged 109.9%

Longitude Capital Partners V, a 10% owner of Veradermics, executed 2 separate purchases totaling 1,075,000 shares (1.08M shares) for $18,275,000.00 at $17.00 per share on 2026-02-05, increasing its holdings from 978,474 shares to 2,053,474 shares (+109.9%). The timing is notable: MANE recently listed 2 trading days prior, and this substantial acquisition at the IPO price suggests a major shareholder's immediate, substantial commitment to the company post-IPO. A cluster of 4 other insiders also bought within the past 14 days, indicating coordinated buying interest. However, this filing contains a derivative-conversion transaction (Table II data not yet populated), so the insider's full position extends beyond the Table I shares shown and should not be construed as a complete equity stake description.

Director Coric Vlad bought 117,646 shares ($2.0M) at $17.00 in 2 transactions; concurrent cluster buy by 4 insiders in IPO window.

Director Coric Vlad executed 2 purchases totaling 117,646 shares for $1,999,982.00 at $17.00 on 2026-02-05, increasing his holdings to 319,398 shares from 201,752 shares—a net increase of 58.3% in his position. The timing coincides with Veradermics' recent listing (2 trading days old as of the transaction date), and the current price of $37.16 reflects a 118% premium to the purchase price, suggesting strong post-IPO momentum. Notably, 4 other insiders also bought within the past 14 days, forming a cluster buy pattern during the early trading window. This concentrated insider purchasing activity during the post-IPO period, combined with the significant position expansion and the parallel activity by multiple directors, signals alignment between management and the offering valuation at a critical early moment for the company's public trading history.